Dapirolizumab Pegol Demonstrates Enhanced Response in Lupus Patients

New data presented by UCB and Biogen Inc. at ACR Convergence 2026 indicates that the investigational biologic dapirolizumab pegol (DZP) improves treatment response rates in systemic lupus erythematosus (SLE) patients. A post-hoc analysis of the Phase 3 PHOENYCS GO study showed that more patients receiving DZP plus standard of care achieved clinically meaningful responses in active organ domains through Week 48. This suggests potential for a new therapeutic option for SLE.